Home / Solutions / Life Sciences
AI value realization for life sciences
Pharma, biotech and medical products already run on evidence. Propelon applies the same discipline to the AI portfolio — across R&D, clinical, regulatory, medical affairs and commercial — so every initiative ends in a number Finance verifies and the regulatory owner attests.
The industry problem
Why AI value stalls here
- AI pilots multiplying across discovery, clinical operations, regulatory writing, pharmacovigilance and the field, with no comparable measure of value between them.
- A validation culture meeting AI velocity: nothing moves without evidence, so unevidenced pilots stall — and evidenced ones wait behind them.
- Cycle-time gains claimed in one function that are never traced to the program, submission or launch they were meant to accelerate.
- AI investment set to rise faster here than in almost any sector, with no system to say which of it paid.
With Propelon
What changes
- Strategic focus areas declared by therapeutic area, function or launch, so intake screens against what the portfolio actually needs.
- Gates that carry evidence as first-class fields — validation status, data provenance, model risk — with a named attestation at each.
- Adoption measured where the work happens, from clinical, regulatory and commercial systems, not from status reports.
- Five value states, never summed: cycle time, quality and cost verified by Finance, with the regulatory or medical owner attesting alongside.
Pharmaceutical and medical-products respondents are the most likely of any sector to expect increased AI investment next year (McKinsey, The state of AI in 2026). Propelon turns that intent into a portfolio that can show what it returned.
Bring R&D and Finance to the demo.
A therapeutic-area or functional lead and a finance partner in the same session make the first 90 days concrete — the record is built for both.